Inhibikase signs $5.66M ATM equity distribution agreement with H.C. Wainwright

Inhibikase Therapeutics, Inc.

Entered into ATM equity offering agreement with H.C. Wainwright for up to $5,659,255 of common stock.
Agent receives 3.0% commission on gross proceeds; company reimburses up to $50k initial legal fees plus $2.5k quarterly.
Sales made under existing effective S-3 shelf registration statement (File No. 333-262551) at market prices.
Company has no obligation to sell shares and may suspend or terminate the agreement at any time.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Inhibikase Therapeutics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at aggregate offering price of up to $5,659,255 (effective 2024-02-01).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Value: aggregate offering price of up to $5,659,255
Effective: 2024-02-01

Exact text from the filing

On February 1, 2024, Inhibikase Therapeutics, Inc. (the “ Company ”) entered into an At The Market Offering Agreement (the “ Agreement ”) with H.C. Wainwright & Co., LLC, as sales agent (the “ Agent ”), pursuant to which the Company may, from time to time, issue and sell shares of its common stock, par value $0.001 per share, in an aggregate offering price of up to $5,659,255 (the “ Shares ”) through the Agent.

View on SEC.gov

271 material agreements filed in the last 30 days. Browse all material agreements →

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-021850

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.